Hinova Pharmaceuticals (SHSE:688302) Total Liabilities: ¥252.12 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688302 Hinova Pharmaceuticals Inc SHSE:688302
24 GF Score
Price ¥37.00
! 2 Warning Signs
View Full Analysis

What is Hinova Pharmaceuticals Total Liabilities?

Hinova Pharmaceuticals SHSE:688302 -14.81% 24 Total Liabilities is ¥252.12 Mil as of Mar. 2026. GuruFocus rates SHSE:688302 with a GF Score™ of 24/100. The stock has 2 warning signs investors should review.

Hinova Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2026 was ¥252.12 Mil.

Hinova Pharmaceuticals's quarterly Total Liabilities declined from Sep. 2025 (¥262.27 Mil) to Dec. 2025 (¥246.19 Mil) but then increased from Dec. 2025 (¥246.19 Mil) to Mar. 2026 (¥252.12 Mil).

Hinova Pharmaceuticals's annual Total Liabilities increased from Dec. 2023 (¥124.48 Mil) to Dec. 2024 (¥169.34 Mil) and increased from Dec. 2024 (¥169.34 Mil) to Dec. 2025 (¥246.19 Mil).

Hinova Pharmaceuticals Total Liabilities Historical Data

* Premium members only.

The historical data trend for Hinova Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hinova Pharmaceuticals Total Liabilities Chart

Hinova Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial 193.59 149.68 124.48 169.34 246.19

Hinova Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 146.19 255.12 262.27 246.19 252.12
SHSE:688302
24GF Score
Hinova Pharmaceuticals Inc SHSE:688302
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hinova Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Hinova Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=125.904+(102.591+17.693
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=246.19

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=1309.746-1063.559
=246.19

Hinova Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=125.08+(102.111+24.932
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=252.12

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=1285.881-1033.757
=252.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of ¥252.12 Mil mean?
Hinova Pharmaceuticals (SHSE:688302) has a Total Liabilities of ¥252.12 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Hinova Pharmaceuticals and its competitors.
Is Hinova Pharmaceuticals' Total Liabilities too high?
Hinova Pharmaceuticals' current Total Liabilities is ¥252.12 Mil. Overall, Hinova Pharmaceuticals has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Hinova Pharmaceuticals' Total Liabilities compare to VRTX and REGN?
Hinova Pharmaceuticals' Total Liabilities of ¥252.12 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Hinova Pharmaceuticals and its competitors. Hinova Pharmaceuticals's current Total Liabilities is ¥252.12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hinova Pharmaceuticals stock overvalued right now?
Hinova Pharmaceuticals (SHSE:688302) has a current Total Liabilities of ¥252.12 Mil. The current Total Liabilities is ¥252.12 Mil. Hinova Pharmaceuticals' overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Hinova Pharmaceuticals (SHSE:688302), the current Total Liabilities is ¥252.12 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hinova Pharmaceuticals Business Description

Address No. 5 Keyuan South Road, No. 2 and 3, 4th Floor, Building 1, Rongyao Building, High-tech Zone, Sichuan Province, Chengdu, CHN, 610041
Hinova Pharmaceuticals Inc is an international drug company based on technology platforms such as deuterium and PROTAC, aiming to develop Best-in-class and First-in-class drugs with major clinical needs. The company focuses on the research and development of drugs in therapeutic areas such as oncology and metabolic diseases, focusing on providing safe, effective and affordable drugs for patients, and is committed to the development and production of drugs with global rights and interests.
24GF Score

Get the complete analysis for SHSE:688302

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥37.00
Price